Magnetic stimulation slows Parkinson progression
- Trial ID
- NCT06002581
- Official Title
- Clinical Study on the Efficacy and Safety of rTMS Regulating Slow-wave Sleep to Delay the Progression of Parkinson's Disease
- Goal
- Magnetic stimulation slows Parkinson progression
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Study Type
- INTERVENTIONAL
- Enrollment
- 56 participants
- Conditions
- Parkinson's Disease
- Interventions
- rTMS real stimulation stage1, rTMS shame stimulation stage1, rTMS real stimulation stage 2
Plain-Language Summary
Goal: The trial aims to slow Parkinson's progression by boosting deep slow-wave sleep, which may help the brain clear toxic proteins and support repair and plasticity linked to symptom worsening. Approach: It uses repetitive transcranial magnetic stimulation, noninvasive magnetic pulses to targeted brain regions to increase slow-wave non-REM sleep; rTMS does not change levodopa itself, so participants keep a stable levodopa dose while researchers test whether better slow-wave sleep affects symptoms or disease course. Eligibility: The study is enrolling right-handed Chinese Han adults aged 50 to 80 with clinically probable or definite PD at Hoehn-Yahr stages 1,4, on a stable levodopa regimen, without major cognitive impairment, prior brain surgery or TMS, significant sleep apnea or other listed contraindications.
Locations
- Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying rTMS real stimulation stage1. Goal: The trial aims to slow Parkinson's progression by boosting deep slow-wave sleep, which may help the brain clear toxic proteins and support repair and plasticity linked to symptom worsening. Approach: It uses repetitive transcranial magnetic stimulation, noninvasive magnetic pulses to targeted brain regions to increase slow-wave non-REM sleep; rTMS does not change levodopa itself, so participants keep a stable levodopa dose while researchers test whether better slow-wave sleep affects symptoms or disease course. Eligibility: The study is enrolling right-handed Chinese Han adults aged 50 to 80 with clinically probable or definite PD at Hoehn-Yahr stages 1,4, on a stable levodopa regimen, without major cognitive impairment, prior brain surgery or TMS, significant sleep apnea or other listed contraindications.
- Who can participate?
- Participants must be between 50 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 11 months.